Filtered By:
Source: Journal of Thrombosis and Haemostasis
Condition: Bleeding

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 40 results found since Jan 2013.

Optimising stroke prevention in elderly patients with atrial fibrillation
This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - August 24, 2016 Category: Hematology Authors: Gregory Y H Lip Tags: Commentary Source Type: research

A Phase II, double‐blind, randomized, parallel group, dose‐finding study of the safety and tolerability of darexaban compared with warfarin in patients with non‐valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL‐2)
ConclusionsIn this Phase II study in patients with NVAF, a lower bleeding rate was observed in the 120 mg daily darexaban group compared with warfarin with a reduction in plasma D‐dimer as marker for hemostasis. Further investigation of the optimal dose of darexaban for the prevention of stroke in patients with NVAF would need to be considered.
Source: Journal of Thrombosis and Haemostasis - July 15, 2015 Category: Hematology Authors: G. Y. H. Lip, J. L. Halperin, P. Petersen, G. M. Rodgers, D. Pall, R. W. Renfurm Tags: Original Article Source Type: research

The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non‐valvular atrial fibrillation: comment
This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - June 30, 2016 Category: Hematology Authors: Simon Mantha, Stephan Moll, Patrick Hilden, Sean Devlin, Adam Rose Tags: Letter ‐ to the Editor Source Type: research

Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in nonvalvular atrial fibrillation patients: A multicenter propensity‐matched analysis
ConclusionsThe heparin bridging therapy increased bleeding without the benefit of preventing stroke at the initiation of OAC in NVAF. Our data suggest that heparin bridging should not be considered at the initiation of OAC in NVAF patients.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - December 4, 2014 Category: Hematology Authors: Tae‐Hoon Kim, Jong‐Youn Kim, Hee‐Sun Mun, Hye‐Young Lee, Yun Ho Roh, Jae‐Sun Uhm, Hui‐Nam Pak, Moon‐Hyoung Lee, Boyoung Joung Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non‐valvular atrial fibrillation patients: a multicenter propensity‐matched analysis
ConclusionsThe heparin‐bridging therapy increased bleeding without the benefit of preventing stroke at the initiation of OAC in NVAF. Our data suggest that heparin bridging should not be considered at the initiation of OAC in NVAF patients.
Source: Journal of Thrombosis and Haemostasis - January 7, 2015 Category: Hematology Authors: T.‐H. Kim, J.‐Y. Kim, H.‐S. Mun, H.‐Y. Lee, Y. H. Roh, J.‐S. Uhm, H.‐N. Pak, M.‐H. Lee, B. Joung Tags: Original Article Source Type: research

Comparing Mortality in Patients with Atrial Fibrillation who are Receiving a Direct Oral Anticoagulant or Warfarin: A Meta‐analysis of Randomized Trials
ConclusionCompared with warfarin therapy for stroke prevention in patients with AF, DOACs significantly reduce all‐cause mortality, vascular mortality and bleeding mortality. This mortality benefit appears to be driven by the reduction in vascular‐ and bleeding‐related mortality which, in turn, may be related to the reduction in intracranial bleeding.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - June 1, 2014 Category: Hematology Authors: A. Liew, M. O'Donnell, J. Douketis Tags: Brief Report ‐ Coagulation Source Type: research

Comparing mortality in patients with atrial fibrillation who are receiving a direct‐acting oral anticoagulant or warfarin: a meta‐analysis of randomized trials
ConclusionAs compared with warfarin therapy for stroke prevention in patients with AF, DOACs significantly reduce all‐cause mortality, vascular mortality, and bleeding mortality. This mortality benefit appears to be driven by the reduction in vascular‐related and bleeding‐related mortality, which, in turn, may be related to the reduction in intracranial bleeding.
Source: Journal of Thrombosis and Haemostasis - July 25, 2014 Category: Hematology Authors: A. Liew, M. O'Donnell, J. Douketis Tags: Brief Report Source Type: research

Acute hemorrhagic complications are associated with lower coated‐platelet levels in non‐lacunar brain infarction
ConclusionsLower levels of procoagulant platelets are associated with acute hemorrhagic complications following non‐lacunar ischemic stroke. These results suggest a role for coated‐platelets in risk/benefit assessment in the early stages of stroke.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - September 1, 2015 Category: Hematology Authors: C. I. Prodan, J. A. Stoner, G. L. Dale Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research

Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: A commentary
The objective of this article is to provide a commentary on the recommendations for stroke prevention from the 2012 focused update of the European Society of Cardiology guidelines on the management of atrial fibrillation and the evidence (or lack of it) supporting these recommendations. These guidelines strongly advocate a major clinical practice shift towards initially focusing on the identification of ‘truly low risk’ patients who do not need any antithrombotic therapy. After this initial decision‐making step, effective stroke prevention – that is, oral anticoagulation therapy (whether as well controlled adjusted...
Source: Journal of Thrombosis and Haemostasis - March 2, 2013 Category: Hematology Authors: Gregory Y H Lip Tags: Review Article Source Type: research

Impact of double‐blind versus open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta‐analysis
ConclusionsOur meta‐analysis showed no significant interaction of study design for the main efficacy and safety outcomes. However, the non‐significantly exaggerated reduction in SSE suggests interdependence of treatment effect and PROBE design, especially for haemorrhagic stroke.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - May 9, 2013 Category: Hematology Authors: Jean‐Christophe Lega, Patrick Mismetti, Michel Cucherat, Thomas Fassier, Laurent Bertoletti, Céline Chapelle, Silvy Laporte Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Impact of double‐blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta‐analysis
ConclusionsOur meta‐analysis showed no significant interaction of study design for the main efficacy and safety outcomes. However, the non‐significantly exaggerated reduction in SSE suggests interdependence of treatment effect and PROBE design, especially for hemorrhagic stroke.
Source: Journal of Thrombosis and Haemostasis - July 15, 2013 Category: Hematology Authors: J.‐C. Lega, P. Mismetti, M. Cucherat, T. Fassier, L. Bertoletti, C. Chapelle, S. Laporte Tags: Original Article Source Type: research

D‐dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial
ConclusionIn anticoagulated patients with AF the level of D‐dimer is related to the risk of stroke, death and bleeding and adds to the predictive value of clinical risk scores. The benefits of apixaban were consistent regardless of the baseline D‐dimer level.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - June 18, 2014 Category: Hematology Authors: Christina Christersson, Lars Wallentin, Ulrika Andersson, John H Alexander, Jack Ansell, Raffaele Caterina, Bernard J Gersh, Christopher B Granger, Michael Hanna, John D Horowitz, Kurt Huber, Steen Husted, Elaine M Hylek, Renato D Lopes, Agneta Siegbahn Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research

Thrombolytic therapy or surgery for valve prosthesis thrombosis: systematic review and meta‐analysis
ConclusionMortality in patients treated by thrombolytic therapy for valve prosthesis thrombosis is significantly lower than in patients treated surgically. As we cannot yet ascertain whether this difference is due to the treatment alone, more studies now are necessary to further clarify these findings.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - April 2, 2014 Category: Hematology Authors: F. M. Castilho, M. R. Sousa, A. L. P. Mendonça, A. L. P. Ribeiro, F. M. Cáceres‐Lóriga Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study
ConclusionA limited number of prediction models is available that predict intracranial hemorrhage or major bleeding in patients on antiplatelet therapy. Methodological quality of the models varied, but was generally low. Predictive performance in patients with cerebral ischemia was poor. In order to reliably predict the risk of bleeding in patients with cerebral ischemia, development of a prediction model according to current methodological standards is needed.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - November 12, 2015 Category: Hematology Authors: Nina A. Hilkens, Ale Algra, Jacoba P. Greving Tags: Original Article ‐ Platelets Source Type: research

Influence of the 3K3A‐activated protein C variant on the plasma clot lysis activity of tPA and of tPA on the variant's anticoagulant activity
This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - September 4, 2013 Category: Hematology Authors: Laurent O. Mosnier, José A. Fernández, Thomas P. Davis, Berislav V. Zlokovic, John H. Griffin Tags: Letter to the Editor Source Type: research